Home Reported Outcomes in PNH

RecruitingOBSERVATIONAL
Enrollment

128

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
OTHER

PNH-relevant therapies

This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.

Trial Locations (1)

07936

RECRUITING

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY